David S Tierney
CIK 1292636 · Pres and CEO · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$174.2K
Companies
7
Total Filings
96
Lifetime Open-Market Net
-$2.81M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Director | 0 | $31.49 | $0 | -$2.94M | 49 | 2026-07-17 |
| ZVRA | Director | 10,835 | $11.82 | $128.1K | $20.7K | 1 | 2023-03-13 |
| ZEVRA THERAPEUTICS, INC. (KMPH) Delisted | Director | 5,835 | $5.81 | $33.9K | $90.1K | 15 | 2022-06-30 |
| Timber Pharmaceuticals, Inc. (BPMX) Delisted | Pres and CEO | 625,000 | — | — | $20.2K | 3 | 2019-06-14 |
| NEXM | Director | 17,863 | $2.58 | $46.1K | $0 | 12 | 2009-10-19 |
| BIOJECT MEDICAL TECHNOLOGIES INC (BJCT) Delisted | Director | 6,000 | — | — | $0 | 6 | 2008-06-16 |
| Valera Pharmaceuticals Inc (VLRX) Delisted | President and CEO | 0 | — | — | $0 | 2 | 2007-04-18 |
Recent Filings · Page 9 of 10
96 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-06-09 | BIOJECT MEDICAL TECHNOLOGIES INC (BJCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-04-28 | CATALYST PHARMACEUTICALS, INC. (CPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-02-29 | NEXM | Grant (A) | +10,227 | $9.0K | EDGAR |
| 2008-01-24 | BIOJECT MEDICAL TECHNOLOGIES INC (BJCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-01-11 | NEXM | Grant (A) | +24,324 | $36.0K | EDGAR |
| 2007-12-18 | BIOJECT MEDICAL TECHNOLOGIES INC (BJCT) Delisted | Exer (M) | +3,000 | $0 | EDGAR |
| 2007-12-07 | BIOJECT MEDICAL TECHNOLOGIES INC (BJCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-10-01 | NEXM | Grant (A) | +20,000 | $32.0K | EDGAR |
| 2007-10-01 | NEXM | Grant (A) | +10,227 | $9.0K | EDGAR |
| 2007-07-02 | NEXM | Grant (A) | +10,227 | $9.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.